R&D | April 17, 2026
Revvity aims to accelerate breakthroughs in cancer research
Revvity is positioning its technologies as a connected engine for discovery
Revvity is positioning its technologies as a connected engine for discovery
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Paves the way for next-gen ultra-precise gas sensing
A major push to sharpen the future of cancer treatment is underway
Subscribe To Our Newsletter & Stay Updated
